An analysis found that MS patients on a less frequent anti-CD20 therapy dosing schedule do not have more relapses or show ...

An international research team has secured nearly $800,000 to advance a potential regenerative therapy for MS toward clinical ...

SHREVEPORT, La. - A cutting-edge clinical trial is now underway in Shreveport, and local patients with Multiple Sclerosis are ...

Dr Devon Conway describes how the upcoming conference is expected to provide important new data on the safety and real-world ...

A Canadian-led international research team, spearheaded by Dr. Fang Liu at the Centre for Addiction and Mental Health (CAMH) ...

A Canadian-led international research team, spearheaded by Dr. Fang Liu at the Centre for Addiction and Mental Health (CAMH) has received nearly $800,000 US ($1,137,868 CAD) in new funding to advance ...

Multiple sclerosis, an autoimmune condition, causes the immune system to mistakenly attack myelin cells, which are protective ...

Background Benign multiple sclerosis (MS), characterised by minimal disability despite long disease duration, remains poorly understood in terms of its determinants and prognostic implications. While ...

Nebraska Medicine has become the first medical center in the world to use allogeneic CAR T-cell therapy to treat multiple sclerosis (MS).

BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in the EU and ...

With two late-stage programs set to read out in the next 48 months, Biogen is translating its wealth of experience in ...